

Human Hair Follicle: An Update on Biology and Perspectives in Hair Growth Disorders Treatment

Brajac, Ines; Vičić, Marijana; Periša, Darinka; Kaštelan, Marija

Source / Izvornik: **Hair Therapy & Transplantation, 2014, 115**

Journal article, Published version

Rad u časopisu, Objavljena verzija rada (izdavačev PDF)

<https://doi.org/10.4172/2167-0951.1000115>

Permanent link / Trajna poveznica: <https://um.nsk.hr/um:nbn:hr:184:367570>

Rights / Prava: [Attribution-NonCommercial-NoDerivatives 4.0 International/Imenovanje-Nekomercijalno-Bez prerada 4.0 međunarodna](#)

Download date / Datum preuzimanja: **2024-08-08**



Repository / Repozitorij:

[Repository of the University of Rijeka, Faculty of Medicine - FMRI Repository](#)



Human Hair Follicle: An Update on Biology and Perspectives in Hair Growth Disorders Treatment

Ines Brajac*, Marijana Vičić, Darinka Periša, Marija Kaštelan

Department of Dermatovenereology, University Hospital Center Rijeka, Croatia

Abstract

The Hair Follicle (HF) is a vital component of mammalian skin and represents a unique, highly regenerative system that undergoes phases of rapid growth, regression, and resting periods. The hair cycling is of profound clinical relevance since majority of the hair growth disorders occur as a result of cycle changes. The influence of many molecules governing the formation of HF has been investigated and many of important cycle mediators have been identified. Cellular and molecular events during cycling are controlled by a network of sequential activation of autocrine, paracrine and endocrine signaling pathways. This implies variations in the expression or activity of the Wnt family molecules, Fibroblast Growth Factor (FGF), Transforming Growth Factor β (TGF- β), Hedgehog pathway, β -Catenin pathway, noggin, transcription factor Stat3, Epidermal Growth Factor (EGF), Insulin Growth Factor-1 (IGF-1), Vascular Endothelial Growth Factor (VEGF), Thyrotropin Releasing Hormone (TRH), Polyamine, Spermidine, Neurotrophins (NT3, NT4), prolactin, retinoids, Bone Morphogenetic Protein 4 (BMP4), cathepsin L, 17- β estradiol, dihydrotestosterone and many others. Despite considerable progress in this area, the key elements of cycle control have not been identified. Therefore, for the most common hair disorders several agents are available, even none of these is curative or preventive. The one of the prime challenges of hair research is a better understanding of the molecular controls of hair cycling and developing drug which would effectively manipulate the cycle. Future therapy strategies will be based on new and better knowledge about the HF biology. Until then, alopecia areata, telogen effluvium and androgenetic alopecia, will remain unsolved medical problems.

Keywords: Hair disorders; Hair follicle; Hair cycle; Alopecia areata; Androgenetic alopecia

Introduction

The Hair Follicle (HF) is a vital component of mammalian skin. Thick scalp hair gives protection from actinic damage, while specialized nasal hairs, eyebrows and eyelashes have some environmental protective role. HF is also involved in sensory perception as a functionally distinct mechanosensory organ, giving the wide tactile sensation range of covered skin surface [1]. Beside the sensory activity role, hair exerts a function of thermoregulation, physical protection, tissue renewal and regeneration, and serves as an instrument of psychosocial communication [2].

Production of a hair is the primary and the most important function of HF. Hair growth does not take place continuously, but in a strictly defined cyclic model that includes periodic regeneration of follicles [3]. A synchronized cycle, seen in mammals, is preparing hair coat for environmental seasonal changes. The purpose of unsynchronized cycle which is seen in human species is not so obvious, but may include cleaning the skin surface of debris and parasites, and secretion of some chemical compounds via trichocytes [4].

Hair growth disorders can be attributed, at large, to a changes in the normal dynamic behaviour of the HF [5]. Since the cycle is regulated by various hormones and growth factors produced both inside and outside the follicles, even small environmental changes may lead to a shortening of the anagen, catagen phase induction, and increasing the number of telogen follicles [6].

Telogen effluvium, Androgenetic Alopecia (AGA), and Alopecia Areata (AA), the frequent hair loss disorders in clinical practice, exemplify how discrete cycling changes translate into significant clinical problems. Therefore, knowing the hair cycle is necessary for understanding the pathogenesis of hair diseases in general. Current hair treatment strategies are symptomatic and nonspecific so nowadays researches aim at developing new, targeted methods. Future strategies planning specific hair disorders therapy will be based on new and better knowledge about the HF biology.

Hair Follicle: A Complex Miniorgan

The hair follicle is perfect and clinically relevant model for biology research. It represents a complex miniorgan that consists of multiple different cell populations which are distinct in their location, function and protein expression characteristics [4,7,8]. The HF is also a uniquely dynamic system that undergoes continuous cycling throughout adult life during which elements of its own morphogenesis are recapitulated [9]. This miniature organ during the normal human lifespan regenerates itself more than 8 to 10 times [2,10]. The transformation process of HF during the cycle arises under the dictates of an enigmatic oscillator system, "the hair cycle clock", and happens simultaneously with changes in the sebaceous gland, perifollicular dermis and subcutis [11-13].

Regarding the origin of its structures, the mature HF can be divided into the mesenchymal part, consisting of the Dermal Papilla (DP) with connective tissue sheath, and the epithelial part, including transient amplifying cells of the hair matrix that envelope the DP, hair shaft, inner root sheath and outer root sheath. Coordination between epithelial and mesenchymal portions of HF as well as bi-directional communication between the pilosebaceous unit and its innervation and vasculature is needed to maintain the cyclic hair follicle growth [14-16].

Functionally, HF can be divided into upper permanent part and

*Corresponding author: Marijana Vičić, Department of Dermatovenereology, University Hospital Center Rijeka, Krešimirova 42, 51 000 Rijeka, Tel: +385 / 51 658 283; E-mail: marijana.vicic@gmail.com

Received December 18, 2013; Accepted January 06, 2014; Published January 11, 2014

Citation: Brajac I, Vičić M, Periša D, Kaštelan M (2014) Human Hair Follicle: An Update on Biology and Perspectives in Hair Growth Disorders Treatment. Hair Ther Transplant 4: 115. doi:10.4172/2167-0951.1000115

Copyright: © 2014 Vičić* M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

deep lower part (including the hair bulb) which is subject of great changes during the cycle. Morphologically, the two parts are divided by a line that lies below the “bulge zone”, an eminent structure at the site of the arrector pili muscle attachment. Bulge zone is the lowest part of the permanent HF segment and it is histological evident as unilateral thickening of the outer root sheath [17]. It is inhabited by epithelial stem cells, precursors of melanocytes, mast cells and Langerhans cells. Thanks to bulge stem cells, HF regenerates itself [18,19].

Stem Cells (SCs), which reside in the adult HF, are the skin’s elixir for regenerating hair, but also for maintaining tissue homeostasis and repairing the epidermis [20]. SCs are nonspecific and pluripotent, having the ability to self-renew and differentiate into multiple cell types. The classical view of SCs depicts them as slowly cycling, relatively undifferentiated cells, with the ability both for self-regeneration and for supplying the rapidly dividing progenitor population [9]. Until now, melanocytic SCs, mesenchymal SCs, mast cells precursors, immature Langerhans cells and neuronal SCs were recognized [21-27].

The Dermal Papilla (DP) functions as the hair signaling center, and represents as a pocket of mesenchymal cells that lies at the hair base [28-30]. The number of DP cells and their secretory activity determines the size of the anagen hair bulb, thickness, length, and the hair shaft diameter [31-33].

The HF can be considered an essentially autonomous organ as it is able to grow after dissection from its neurovascular supply and transplantation into another part of the integument [34]. In addition, isolated human HF can be maintained in organ culture, exhibiting emergent properties of great biological relevance: controlled cell proliferation, differentiation, apoptosis and organ regeneration [35,36].

Hair Cycle

The hair cycle is traditionally divided into the growth phase (anagen I-VI), regression phase (catagen) and resting phase (telogen) [2]. Hair loss has recently been recognized as a separate active process that is called exogen, while kenogen is a brief interval in which the HF remains empty [37].

Anagen phase has significantly higher metabolic activity among matrix keratinocytes that produce the hair fiber and inner root sheath. It is divided into six subphases defined by specific morphological criteria, one of which is called pro-anagen, including phases I to V. The met-anagen phase follows, which leads to hair growth on the epidermis surface [38]. During the end of the anagen, follicle lies deep, firmly anchored in the subcutaneous tissue, while the bulb changes the position by moving more superficial, below the insertion of the arrector pili muscle. Anagen phase ends with the involution of HF, apoptosis and terminal differentiation [39-41].

Catagen is the time of involution. It is a short transitional phase of cycle between anagen and telogen, which lasts between two and four weeks. In this phase follicle undergoes a series of morphological and molecular changes that are associated with apoptosis. The first sign of involution is termination of bulb melanin production. Matrix melanocytes stop producing melanin and absorb dendrites, and keratinocytes cease proliferation and undergo terminal differentiation [5]. During catagen, the population of stem cells located lateral to the dermal papilla is spared from apoptosis, allowing the repopulation in the early anagen [33].

After regression, the follicle enters the telogen phase, which is expressed by relative rest in terms of activation and proliferation. Telogen phase lasts three to four months. The hair is no longer firmly

anchored in the tissue, the link between lower part of hair and follicular sac disappears, and the hair falls out.

Recent researchers have found that the hair loss is controlled; active process that significantly differs from inaction during telogen [42]. Even the nature of the process is not yet solved; the morphology of hair root suggests that this process, called exogen, involves proteolytic events among cells in the base of telogen hair [43].

Kenogen is interval in which the hair follicle remains empty after the telogen hair loss and before the outbreak of a new anagen hair. Number of hairs in kenogen increases parallel with the number of vellus hair and reducing normal hair cycles, which is the main feature of AGA deterioration [44].

Regulation of Hair Cycle

Since the majority of hair growth disorders occur as a result of the hair cycle changes, HF cycling is of profound clinical relevance. The concept that skin appendage formation at a given location and time is the result of interacting stimulatory and inhibitory signals exist for the long time; these not only consist of secreted molecules and changes in the expression of receptors, but also of changes in tissue biology and underlie prominent epigenetic controls [45,46].

By recent theory, the cycling is caused by rhythmic signal transducers changes in the bulge zone and dermal papilla region, with complex processes that are the consequences of follicular stem cells and dermal papilla cells interactions. Although HF ‘system’ is highly sensitive to extra-follicular neural and vascular signals thus increasing the level of system complexity, basic autonomous clock driving the HF cycle reside in the HF itself [10,15,47,48].

In any case, cellular and molecular events during differentiation of HF are controlled by a complex network of sequential activation of autocrine, paracrine and endocrine signaling pathways. This implies variations in the expression or activity of numerous cytokines, hormones, neurotransmitters, transcription factors and enzymes in the key compartments of HF.

The development of skin appendage such as hair is regulated by signaling molecules of the Wnt family, Fibroblast Growth Factor (FGF), transforming growth factor β (TGF- β), and Hedgehog pathways [49]. Hair follicle regeneration begins when signals from the mesenchyme-derived dermal papilla cells reach multipotent epidermal stem cells in the bulge region. Key inducers of anagen, the rapid growth hair cycle phase, including Wnt family proteins, β -Catenin pathway, noggin, and the transcription factor Stat3 [50]. Signal transducer and activator of transcription 3 (Stat3) plays critical roles in biological activities and contributes to HF growth. Stat3 is a latent cytoplasmic protein that conveys signals to the nucleus upon stimulation with IL-6, Epidermal Growth Factor (EGF), and many other cytokines/growth factors [51]. EGF probably triggers multiplication and proliferation of outer root sheath follicle cells that leads to the formation of new hair follicles. Another EGF role is probably anagen to catagen transition [52].

Wnt/ β -catenin signaling is also known to positively affect mammalian hair growth. For example, HF stem cell differentiation is inhibited through a cross talk between Wnt/ β -catenin and androgen signalling in dermal papilla cells from patients with androgenetic alopecia [53].

Sonic Hedgehog Proteins (Shh) and Hepatic Growth Factor (HGF) furthermore promote anagen development. Upregulation of Shh activity functions as a biologic switch that induces resting hair follicles

to enter anagen with consequent hair growth. Sonic hedgehog is one of the earliest genes found to be expressed in the hair placode. Continuous labeling of Shh-expressing cells showed that their progeny, with rare exceptions, form all structures in the HF. Shh expression is necessary also for the embryonic development of hair follicles [10,54-58].

The duration of anagen phase prolong Insulin Growth Factor-1 (IGF-1), Vascular Endothelial Growth Factor (VEGF) and Thyrotropin-Releasing Hormone (TRH). IGF-1 and IGF-2 are dose-dependent HF growth stimulators that also prevent the entry of follicles into catagen. It is possible that both of these growth factors are key physiological hair cycle regulators. Hypothesis is supported by a noticeable decline in the expression of mRNA for IGF-1 during early catagen [59,60].

TRH promotes hair-shaft elongation, prolongs the anagen and antagonizes its termination by Transforming Growth Factor- β 2 (TGF- β 2) [59]. Human HFs are direct targets of thyroid hormones and demonstrate that T3 and/or T4 modulate multiple hair biology parameters, ranging from HF cycling to pigmentation. Human scalp HFs are both a source and a target of TRH, which operates as a potent hair-growth stimulator [59,61].

Important anagen prolongator/catagen inhibitor is also the key polyamine-spermidine. Polyamines are multifunctional polycationic aliphatic amines which except serving as metabolic and nutrients regulators, also have been implicated as mediators of key cell functions, such as proliferation, migration and differentiation. Spermidine is a potent stimulator of human hair growth and a previously unknown modulator of human epithelial stem cell biology [62,63].

Finally, an important role in the regenerating hair follicle, play hair follicle stem cell marker nestin, located in the dermal papilla [64].

Anagen is terminated by the concurrent decreasing of anagen upholding factors (IGF-1, HGF, FGF-5S) and increasing of hair growth inhibitors, like members of the transforming growth factor (TGF- β 1, TGF- β 2), fibroblast growth factor. Inhibition of TGF- β 2 activity at receptor level significantly impairs the maturation of follicles and folliculogenesis [65].

Dickkopf 1 (DKK-1) is involved in anagen-to-catagen transition in the hair cycle by regulating the activity of follicular keratinocytes. Moreover, it is observed that recombinant human DKK-1 (rhDKK-1) blocks canonical Wnt-mediated activation of β -catenin signaling and induces the proapoptotic protein Bax, resulting in apoptosis in outer root sheath keratinocytes [66]. Besides, the molecular interaction between downregulating effectors of TNF-signalling and keratin 17 (K17) may be partly responsible for controlling catagen entry by regulating the rate of apoptosis [2]. Last decade has revealed a pivotal role for the TNF family ligand Ectodysplasin (Eda) in multiple steps of hair morphogenesis, from initiation to differentiation. Other members of the TNF superfamily such as Rank ligand, lymphotoxins and TNF have recently been linked with specific aspects of skin appendage biology including hair shaft formation, and hair follicle cycling [49].

Other involved controlling anagen-catagen transformation molecules are neurotrophins NT-3, NT-4, as well as prolactin and retinoids. Prolactin participates in the regulation of anagen and telogen initiation, and is produced by the follicle itself. Recent studies identify PRL as a major, clinically relevant, novel neuroendocrine regulator of both human keratin expression and human epithelial stem cell biology in situ [10,50,67,68].

The signaling that controls hair cycle resting phase is only partly understood. Telogen concurs with major gene activity changes and

some proteins, like estrogen receptor, are noticeably increased, so this phase is not really quiescent as traditionally described. On the contrary telogen probably represents a key stage in hair cycle control.

The follicle in telogen arrest Bone Morphogenetic Protein 4 (BMP4) and 17- β estradiol [50]. BMPs are diffusible molecules involved in a variety of cellular interactions during development. It is proposed that about the stage of terminal division, the balance between BMP and BMP-inhibitory signals regulates survival and specification of hair-cell precursors [69].

Hair cycle resting phase is regulated also by cyclic epithelial Fibroblast Growth Factor (FGF18). Signaling FGF18 is expressed in a hair stem cell niche throughout telogen, and that it regulates the hair cycle through the non-growth phases. FGF affects follicular morphogenesis, participates in the regulation of mitotic activity and differentiation. Receptors for this growth factor have been identified in the follicular papilla and in the basal layer of epidermal keratinocytes [70].

The cycle stage, called exogen, has its own control mechanisms and it is presumed that its regulators are protease cathepsin L and Msx-2 [2].

Regarding hormonal influence, autocrine and paracrine factors produced by balding DP cells following Dihydrotestosterone (DHT)-driven alterations are believed to be key factors involved in male pattern baldness. IL-6 is upregulated in balding DP cells compared with non-balding DP cells. Dihydrotestosterone-inducible IL-6 inhibits elongation of human hair shafts by suppressing matrix cell proliferation and promotes regression of hair follicles [71]. 17 β -estradiol (E2) inhibits hair shaft elongation and anagen prolongation in human female occipital hair follicles, whereas in male stimulates hair shaft elongation of frontotemporal scalp follicles [50].

In conclusion, even mostly through mouse models studies, our knowledge of the HF biology is continuously increasing. The promising research approach would be to screen the human HF for the expression of yet recognized mammalian clock genes [72].

The Perspectives in Hair Growth Disorders Treatment

It is perfectly clear that a hair growth disorders can be attributed, at large, to a changes in the normal dynamic behaviour of the HF. Logical conclusion appears that the hair growth disorders could be treated by inhibiting premature transition to catagen phase and/or stimulating the transition from telogen into the anagen phase. However, the key elements of cycle regulation have not been identified. Although all yet recognized molecules offering themselves to be exploited as chemical tools for hair disorders treatment, still remains to synthesize drugs which would effectively manipulate the cycle [6].

Plenty therapeutic agents have been tried as a potent hair cycle-modulators with with variable efficacy and safety profiles. These agents among others include Cyclosporin A (CsA), topical immunophilin ligands, prostaglandin, ezetimibe and simvastatin, minoxidil, retinoids, estrogen, adenosin, calcitriol, estradiol, and prednisolon, zinc, and candida antigen [73-84].

For the most common hair disorders several agents are currently available. The first line of treatment in AGA is still minoxidil, despite of low success rate and speculative mechanism of action. The finasteride inhibits the production of the male hormone dihydrotestosterone but as with minoxidil, one's previous degree of hair loss returns when finasteride is discontinued [85]. Treatment options for female AGA

also include the androgen receptor antagonists spironolactone and cyproterone acetate [86,87]. Considering AA treatment, except for topical immunotherapy and corticosteroids, there are few published studies on long-term therapeutic success of available therapeutic agents. Biologics have also been tried, but shown either development of AA or complete failure to respond to different TNF alpha inhibitors, including adalimumab, infliximab and etanercept [88-91].

Regarding perspectives, a studies have focused on various innovative pharmacologic targets, but also on some well known molecules. The role of prolactin receptor antagonists, as well as the regulators of thyroid hormones, deserves to be the subject of further research. Also, the relation between vitamin D levels, vitamin D receptor and hair cycling, specifically anagen initiation, represent an attractive area of research nowadays [92].

New drug treatment opportunities for AA also include use of drugs that block the NKGD-activating ligand and NKG2D receptor interaction, halt activated T cells, or modificate the cytokine network [93].

Calcitonin Gene-Related Peptide (CGRP) may award relative protection from interferon- γ -induced collapse of human hair follicle immune privilege and might help to retard AA progression [94]. Also, Fuzzy (fz), an autosomal recessive mutation that is involved in controlling catagen and anagen initiation, is an exciting target that maybe drives HF cycling [95].

Recently, autologous platelet-rich plasma (PRP) has attracted attention in plastic surgery and dermatology, for its ability to promote wound healing and to increase hair density [96].

The new studies also make a substantial contribution towards the development of transplantation therapy for skin and skin appendages, even the autologous transplantation of HF is already an accepted treatment for AGA [97].

There are also numerous ongoing studies, that explore the possibilities of using stem cells in treating hair growth disorders. Theoretically it would be possible to regenerate HF cultivating autologous dermal papilla cells and transplanting them to the hairless skin. This hypothetical process of breeding HF would enable the efficient compensation of the lost hair when all other options fail [98].

Conclusion

Recent years have witnessed a considerable progress in the research focused on treatment of hair disorders, but with limited success. Therefore, one of the prime challenges of modern hair research is a more profound understanding of the molecular controls of hair follicle cycling. Common diseases such as alopecia areata, telogen effluvium and AGA, until than will remain the unsolved medical problems.

References

1. Li L, Rutlin M, Abraira VE, Cassidy C, Kus L, et al. (2011) The functional organization of cutaneous low-threshold mechanosensory neurons. *Cell* 147: 1615-1627.
2. Schneider MR, Schmidt-Ullrich R, Paus R (2009) The hair follicle as a dynamic miniorgan. *Curr Biol* 19: R132-142.
3. Hardy MH (1992) The secret life of the hair follicle. *Trends Genet* 8: 55-61.
4. Stenn KS, Paus R (2001) Controls of hair follicle cycling. *Physiol Rev* 81: 449-494.
5. Stenn KS, Paus R (1999) What controls hair follicle cycling? *Exp Dermatol* 8: 229-233.
6. Al-Nuaimi Y, Baier G, Watson RE, Chuong CM, Paus R (2010) The cycling hair follicle as an ideal systems biology research model. *Exp Dermatol* 19: 707-713.
7. Fuchs E (1998) Beauty is skin deep: the fascinating biology of the epidermis and its appendages. *Harvey Lect* 94: 47-77.
8. Paus R, Cotsarelis G (1999) The biology of hair follicles. *N Engl J Med* 341: 491-497.
9. Yu BD, Mukhopadhyay A, Wong C (2008) Skin and hair: models for exploring organ regeneration. *Hum Mol Genet* 17: R54-59.
10. Paus R, Foitzik K (2004) In search of the "hair cycle clock": a guided tour. *Differentiation* 72: 489-511.
11. Fuchs E, Merrill BJ, Jamora C, DasGupta R (2001) At the roots of a never-ending cycle. *Dev Cell* 1: 13-25.
12. Botchkarev VA, Paus R (2003) Molecular biology of hair morphogenesis: development and cycling. *J Exp Zool B Mol Dev Evol* 298: 164-180.
13. Yano K, Brown LF, Lawler J, Miyakawa T, Detmar M (2003) Thrombospondin-1 plays a critical role in the induction of hair follicle involution and vascular regression during the catagen phase. *J Invest Dermatol* 120: 14-19.
14. Rendl M, Lewis L, Fuchs E (2005) Molecular dissection of mesenchymal-epithelial interactions in the hair follicle. *PLoS Biol* 3: e331.
15. Paus R, Müller-Röver S, Botchkarev VA (1999) Chronobiology of the hair follicle: hunting the "hair cycle clock". *J Invest Dermatol Symp Proc* 4: 338-345.
16. Tobin DJ, Gunin A, Magerl M, Handjiski B, Paus R (2003) Plasticity and cytokinetic dynamics of the hair follicle mesenchyme: implications for hair growth control. *J Invest Dermatol* 120: 895-904.
17. Blanpain C, Lowry WE, Geoghegan A, Polak L, Fuchs E (2004) Self-renewal, multipotency, and the existence of two cell populations within an epithelial stem cell niche. *Cell* 118: 635-648.
18. Cotsarelis G, Sun TT, Lavker RM (1990) Label-retaining cells reside in the bulge area of pilosebaceous unit: Implications for follicular stem cells, hair cycle and skin carcinogenesis. *Cell* 61: 1329-1337.
19. Morris RJ, Liu Y, Marles L, Yang Z, Trempus C, et al. (2004) Capturing and profiling adult hair follicle stem cells. *Nat Biotechnol* 22: 411-417.
20. Fuchs E (2008) Skin stem cells: rising to the surface. *J Cell Biol* 180: 273-284.
21. Nishimura EK, Jordan SA, Oshima H, Yoshida H, Osawa M, et al. (2002) Dominant role of the niche in melanocyte stem-cell fate determination. *Nature* 416: 854-860.
22. Lako M, Armstrong L, Cairns PM, Harris S, Hole N, et al. (2002) Hair follicle dermal cells repopulate the mouse haematopoietic system. *J Cell Sci* 115: 3967-3974.
23. Kumamoto T, Shalhevet D, Matsue H, Mummert ME, Ward BR, et al. (2003) Hair follicles serve as local reservoirs of skin mast cell precursors. *Blood* 102: 1654-1660.
24. Gilliam AC, Kremer IB, Yoshida Y, Stevens SR, Tootell E, et al. (1998) The human hair follicle: a reservoir of CD40+ B7-deficient Langerhans cells that repopulate epidermis after UVB exposure. *J Invest Dermatol* 110: 422-427.
25. Amoh Y, Li L, Campillo R, Kawahara K, Katsuoka K, et al. (2005) Implanted hair follicle stem cells form Schwann cells that support repair of severed peripheral nerves. *Proc Natl Acad Sci U S A* 102: 17734-17738.
26. Oliver RF (1966) Whisker growth after removal of the dermal papilla and lengths of follicle in the hooded rat. *J Embryol Exp Morphol* 15: 331-347.
27. Jahoda CA (2003) Cell movement in the hair follicle dermis - more than a two-way street? *J Invest Dermatol* 121: ix-xi.
28. Amoh Y, Li L, Katsuoka K, Penman S, Hoffman RM (2005) Multipotent nestin-positive, keratin-negative hair-follicle bulge stem cells can form neurons. *Proc Natl Acad Sci U S A* 102: 5530-5534.
29. Arnold I, Watt FM (2001) c-Myc activation in transgenic mouse epidermis results in mobilization of stem cells and differentiation of their progeny. *Curr Biol* 11: 558-568.

30. Morris RJ (2000) Keratinocyte stem cells: targets for cutaneous carcinogens. *J Clin Invest* 106: 3-8.
31. Shimomura Y, Christiano AM (2010) Biology and genetics of hair. *Annu Rev Genomics Hum Genet* 11: 109-132.
32. Pasolli HA (2011) The hair follicle bulge: a niche for adult stem cells. *Microsc Microanal* 17: 513-519.
33. Driskell RR, Clavel C, Rendl M, Watt FM (2011) Hair follicle dermal papilla cells at a glance. *J Cell Sci* 124: 1179-1182.
34. Maurer M, Peters EM, Botchkarev VA, Paus R (1998) Intact hair follicle innervation is not essential for anagen induction and development. *Arch Dermatol Res* 290: 574-578.
35. Philpott MP, Green MR, Kealey T (1990) Human hair growth in vitro. *J Cell Sci* 97: 463-471.
36. Philpott MP, Sanders DA, Kealey T (1996) Whole hair follicle culture. *Dermatol Clin* 14: 595-607.
37. Paus R, Christoph T, Müller-Röver S (1999) Immunology of the hair follicle: a short journey into terra incognita. *J Invest Dermatol Symp Proc* 4: 226-234.
38. Reynolds AJ, Jahoda CA (1991) Hair follicle stem cells? A distinct germinative epidermal cell population is activated in vitro by the presence of hair dermal papilla cells. *J Cell Sci* 99: 373-385.
39. Lindner G, Botchkarev VA, Botchkareva NV, Ling G, van der Veen C, et al. (1997) Analysis of apoptosis during hair follicle regression (catagen) *Am J Pathol* 151: 1601-1617.
40. Mecklenburg L, Tobin DJ, Müller-Röver S, Handjiski B, Wendt G, et al. (2000) Active hair growth (anagen) is associated with angiogenesis. *J Invest Dermatol* 114: 909-916.
41. Peters EM, Botchkarev VA, Botchkareva NV, Tobin DJ, Paus R (2001) Hair-cycle-associated remodeling of the peptidergic innervation of murine skin, and hair growth modulation by neuropeptides. *J Invest Dermatol* 116: 236-245.
42. Stenn K (2005) Exogen is an active, separately controlled phase of the hair growth cycle. *J Am Acad Dermatol* 52: 374-375.
43. Koch PJ, Mahoney MG, Cotsarelis G, Rothenberger K, Lavker RM, et al. (1998) Desmoglein 3 anchors telogen hair in the follicle. *J Cell Sci* 111: 2529-2537.
44. Rebera A, Guarrera M (2002) Kenogen. A new phase of the hair cycle? *Dermatology* 205: 108-110.
45. Chuong CM, Jung HS, Noden D, Widell RB (1998) Lineage and pluripotentiality of epithelial precursor cells in developing chicken skin. *Biochem Cell Biol* 76: 1069-1077.
46. Chuong CM, Wu P, Plikus M, Jiang TX, Bruce Widell R (2006) Engineering stem cells into organs: topobiological transformations demonstrated by beak, feather, and other ectodermal organ morphogenesis. *Curr Top Dev Biol* 72: 237-274.
47. Itami S (2008) [Hair follicle regeneration]. *Nihon Rinsho* 66: 892-896.
48. Schmidt-Ullrich R, Paus R (2005) Molecular principles of hair follicle induction and morphogenesis. *Bioessays* 27: 247-261.
49. Mikkola ML (2008) TNF superfamily in skin appendage development. *Cytokine Growth Factor Rev* 19: 219-230.
50. Krause K, Foitzik K (2006) Biology of the hair follicle: the basics. *Semin Cutan Med Surg* 25: 2-10.
51. Sano S, Chan KS, DiGiovanni J (2008) Impact of Stat3 activation upon skin biology: a dichotomy of its role between homeostasis and diseases. *J Dermatol Sci* 50: 1-14.
52. Philpott MP, Kealey T (1994) Effects of EGF on the morphology and patterns of DNA synthesis in isolated human hair follicles. *J Invest Dermatol* 102: 186-191.
53. Leirós GJ, Attorresi AI, Balañá ME (2012) Hair follicle stem cell differentiation is inhibited through cross-talk between Wnt/ β -catenin and androgen signalling in dermal papilla cells from patients with androgenetic alopecia. *Br J Dermatol* 166: 1035-1042.
54. Lindner G, Menrad A, Gherardi E, Merlino G, Welker P, et al. (2000) Involvement of hepatocyte growth factor/scatter factor and met receptor signaling in hair follicle morphogenesis and cycling. *FASEB J* 14: 319-332.
55. Levy V, Lindon C, Harfe BD, Morgan BA (2005) Distinct stem cell populations regenerate the follicle and interfollicular epidermis. *Dev Cell* 9: 855-861.
56. Bitgood MJ, McMahon AP (1995) Hedgehog and Bmp genes are coexpressed at many diverse sites of cell-cell interaction in the mouse embryo. *Dev Biol* 172: 126-138.
57. Cui CY, Kunisada M, Childress V, Michel M, Schlessinger D (2011) Shh is required for Tabby hair follicle development. *Cell Cycle* 10: 3379-3386.
58. Sato N, Leopold PL, Crystal RG (1999) Induction of the hair growth phase in postnatal mice by localized transient expression of Sonic hedgehog. *J Clin Invest* 104: 855-864.
59. Gáspár E, Hardenbicker C, Bodó E, Wenzel B, Ramot Y, et al. (2010) Thyrotropin releasing hormone (TRH): a new player in human hair-growth control. *FASEB J* 24: 393-403.
60. Philpott MP, Sanders DA, Kealey T (1994) Effects of insulin and insulin-like growth factors on cultured human hair follicles: IGF-I at physiologic concentrations is an important regulator of hair follicle growth in vitro. *J Invest Dermatol* 102: 857-861.
61. van Beek N, Bodó E, Kromminga A, Gáspár E, Meyer K, et al. (2008) Thyroid hormones directly alter human hair follicle functions: anagen prolongation and stimulation of both hair matrix keratinocyte proliferation and hair pigmentation. *J Clin Endocrinol Metab* 93: 4381-4388.
62. Ramot Y, Pietilä M, Giuliani G, Rinaldi F, Alhonen L, et al. (2010) Polyamines and hair: a couple in search of perfection. *Exp Dermatol* 19: 784-790.
63. Ramot Y, Tiede S, Biró T, Abu Bakar MH, Sugawara K, et al. (2011) Spermidine promotes human hair growth and is a novel modulator of human epithelial stem cell functions. *PLoS One* 6: e22564.
64. Amoh Y, Maejima H, Niiyama S, Mii S, Hamada Y, et al. (2011) Hair follicle stem cell marker nestin expression in regenerating hair follicles of patients with alopecia areata. *Eur J Dermatol* 21: 209-212.
65. Hibino T, Nishiyama T (2004) Role of TGF- β 2 in the human hair cycle. *J Dermatol Sci* 35: 9-18.
66. Kwack MH, Kim MK, Kim JC, Sung YK (2012) Dickkopf 1 promotes regression of hair follicles. *J Invest Dermatol* 132: 1554-1560.
67. Foitzik K, Langan EA, Paus R (2009) Prolactin and the skin: a dermatological perspective on an ancient pleiotropic peptide hormone. *J Invest Dermatol* 129: 1071-1087.
68. Ramot Y, Biró T, Tiede S, Tóth BI, Langan EA, et al. (2010) Prolactin—a novel neuroendocrine regulator of human keratin expression in situ. *FASEB J* 24: 1768-1779.
69. Pujades C, Kamaid A, Alsina B, Giraldez F (2006) BMP-signaling regulates the generation of hair-cells. *Dev Biol* 292: 55-67.
70. Kimura-Ueki M, Oda Y, Oki J, Komi-Kuramochi A, Honda E, et al. (2012) Hair cycle resting phase is regulated by cyclic epithelial FGF18 signaling. *J Invest Dermatol* 132: 1338-1345.
71. Kwack MH, Ahn JS, Kim MK, Kim JC, Sung YK (2012) Dihydrotestosterone-inducible IL-6 inhibits elongation of human hair shafts by suppressing matrix cell proliferation and promotes regression of hair follicles in mice. *J Invest Dermatol* 132: 43-49.
72. Badiu C (2003) Genetic clock of biologic rhythms. *J Cell Mol Med* 7: 408-416.
73. Yamamoto S, Kato R (1994) Hair growth-stimulating effects of cyclosporin A and FK506, potent immunosuppressants. *J Dermatol Sci* 7 Suppl: S47-54.
74. Maurer M, Handjiski B, Paus R (1997) Hair growth modulation by topical immunophilin ligands: induction of anagen, inhibition of massive catagen development, and relative protection from chemotherapy-induced alopecia. *Am J Pathol* 150: 1433-1441.
75. Johnstone MA, Albert DM (2002) Prostaglandin-induced hair growth. *Surv Ophthalmol* 47 Suppl 1: S185-202.
76. Ali A, Martin JM 4th (2010) Hair growth in patients alopecia areata totalis after treatment with simvastatin and ezetimibe. *J Drugs Dermatol* 9: 62-64.
77. Ramelet AA (1986) Minoxidil induces selective regrowth of androgenetic dependent hair. *Dermatologica* 173: 301-302.
78. Foitzik K, Spexard T, Nakamura M, Halsner U, Paus R (2005) Towards dissecting the pathogenesis of retinoid-induced hair loss: all-trans retinoic acid induces premature hair follicle regression (catagen) by upregulation of transforming growth factor- β 2 in the dermal papilla. *J Invest Dermatol* 124: 1119-1126.

79. Ohnemus U, Unalan M, Handjiski B, Paus R (2004) Topical estrogen accelerates hair regrowth in mice after chemotherapy-induced alopecia by favoring the dystrophic catagen response pathway to damage. *J Invest Dermatol* 122: 7-13.
80. Oura H, Iino M, Nakazawa Y et al. (2008) Adenosine increases anagen hair growth and thick hairs in Japanese women with female pattern hair loss: a pilot, double-blind, randomized, placebo-controlled trial. *J Dermatol* 35: 763-767.
81. Paus R, Schilli MB, Handjiski B, Menrad A, Henz BM, et al. (1996) Topical calcitriol enhances normal hair regrowth but does not prevent chemotherapy-induced alopecia in mice. *Cancer Res* 56: 4438-4443.
82. Bodó E, van Beek N, Naumann V, Ohnemus U, Brzoska T, et al. (2009) Modulation of chemotherapy-induced human hair follicle damage by 17-beta estradiol and prednisolone: potential stimulators of normal hair regrowth by "dystrophic catagen" promotion? *J Invest Dermatol* 129: 506-509.
83. Park H, Kim CW, Kim SS, Park CW (2009) The therapeutic effect and the changed serum zinc level after zinc supplementation in alopecia areata patients who had a low serum zinc level. *Ann Dermatol* 21: 142-146.
84. Rosenberg EW, Skinner RB Jr (2006) Immunotherapy of alopecia areata with intralesional *Candida* antigen. *Pediatr Dermatol* 23: 299.
85. Sinclair R, Patel M, Dawson TL Jr, Yazdabadi A, Yip L, et al. (2011) Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness. *Br J Dermatol* 165 Suppl 3: 12-18.
86. Rathnayake D, Sinclair R (2010) Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. *Dermatol Clin* 28: 611-618.
87. Rafi AW, Katz RM (2011) Pilot Study of 15 Patients Receiving a New Treatment Regimen for Androgenic Alopecia: The Effects of Atopy on AGA. *ISRN Dermatol* 2011: 241953.
88. Garcia Bartels N, Lee HH, Worm M, Burmester GR, Sterry W, et al. (2006) Development of alopecia areata universalis in a patient receiving adalimumab. *Arch Dermatol* 142: 1654-1655.
89. Pelivani N, Hassan AS, Braathen LR, Hunger RE, Yawalkar N (2008) Alopecia areata universalis elicited during treatment with adalimumab. *Dermatology* 216: 320-323.
90. Etefagh L, Nedorost S, Mirmirani P (2004) Alopecia areata in a patient using infliximab: new insights into the role of tumor necrosis factor on human hair follicles. *Arch Dermatol* 140: 1012.
91. Posten W, Swan J (2005) Recurrence of alopecia areata in a patient receiving etanercept injections. *Arch Dermatol* 141: 759-760.
92. Amor KT, Rashid RM, Mirmirani P (2010) Does D matter? The role of vitamin D in hair disorders and hair follicle cycling. *Dermatol Online J* 16: 3.
93. Hordinsky MK (2011) Treatment of alopecia areata: "What is new on the horizon?". *Dermatol Ther* 24: 364-368.
94. Kinori M, Bertolini M, Funk W, Samuelov L, Meyer KC, et al. (2012) Calcitonin gene-related peptide (CGRP) may award relative protection from interferon- β -induced collapse of human hair follicle immune privilege. *Exp Dermatol* 21: 223-226.
95. Mecklenburg L, Tobin DJ, Cirlan MV, Craciun C, Paus R (2005) Premature termination of hair follicle morphogenesis and accelerated hair follicle cycling in *lasi congenital atrichia (fzica)* mice points to fuzzy as a key element of hair cycle control. *Exp Dermatol* 14: 561-570.
96. Li ZJ, Choi HI, Choi DK et al. (2012) Autologous Platelet-Rich Plasma: A Potential Therapeutic Tool for Promoting Hair Growth. *Dermatol Surg* 38(7 Pt 1).
97. Sato A, Toyoshima KE, Toki H, Ishibashi N, Asakawa K, et al. (2012) Single follicular unit transplantation reconstructs arrector pili muscle and nerve connections and restores functional hair follicle piloerection. *J Dermatol* 39: 682-687.
98. Yoshida R, Tanaka K, Amagai M, Ohyama M (2011) Involvement of the bulge region with decreased expression of hair follicle stem cell markers in senile female cases of alopecia areata. *J Eur Acad Dermatol Venereol* 25: 1346-1350.

Citation: Brajac I, Vičić M, Periša D, Kaštelan M (2014) Human Hair Follicle: An Update on Biology and Perspectives in Hair Growth Disorders Treatment. *Hair Ther Transplant* 4: 115. doi:[10.4172/2167-0951.1000115](https://doi.org/10.4172/2167-0951.1000115)

Submit your next manuscript and get advantages of OMICS Group submissions

Unique features:

User friendly/feasible website-translation of your paper to 50 world's leading languages
Audio Version of published paper
Digital articles to share and explore

Special features:

300 Open Access Journals
25,000 editorial team
21 days rapid review process
Quality and quick editorial, review and publication processing
Indexing at PubMed (partial), Scopus, EBSCO, Index Copernicus and Google Scholar etc
Sharing Option: Social Networking Enabled
Authors, Reviewers and Editors rewarded with online Scientific Credits
Better discount for your subsequent articles

Submit your manuscript at: <http://www.omicsonline.org/submission>

